Scott Garland is a venture partner at Vida Ventures and an advisor for Google Ventures. Mr. Garland most recently served as the chief executive officer of PACT Pharma, an immuno-oncology company. Prior to PACT, he served as president and chief executive officer of Portola Pharmaceuticals until it was acquired by Alexion Pharmaceuticals in 2020 for $1.4B. Before joining Portola, Mr. Garland was at Relypsa, where he served first as chief commercial officer and then as president after Relypsa’s acquisition by Vifor Pharma for $1.5B. Prior to Relypsa, Mr. Garland served as executive vice president and chief commercial officer of Exelixis. Mr. Garland has held numerous other commercial leadership roles at Genentech, Amgen and Merck, including leading the commercial franchises for two multi-billion-dollar therapies – Avastin® and Rituxan®. He currently serves as a member of the board of directors of Day One Pharmaceuticals, Inc., Olema Oncology, and ALX Oncology. He previously served on the board of directors of Karyopharm Therapeutics and Calithera Biosciences. He holds a B.S. in biological sciences from California Polytechnic State University (San Luis Obispo) and an MBA from Duke University’s Fuqua School of Business.